Evidence map›Paper›PMID 24515567›Full record

ArticleAnnals of surgical oncology2014

Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe.

Floris P R Verbeek, Joost R van der Vorst, Quirijn R J G Tummers, Martin C Boonstra, Karien E de Rooij, Clemens W G M Löwik, A Rob P M Valentijn, Cornelis J H van de Velde, Hak Soo Choi, John V Frangioni and 1 more

Abstract read
In one paragraph

Article in Annals of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Near-Infrared Fluorescent Agent forFrontiers in oncology · 2021
    Article
  7. Review
  8. Article
  9. Fluorescence Image-Guided Surgery - a Perspective on Contrast Agent Development.Proceedings of SPIE--the International Society for Optical Engineering · 2020
    Article
  10. Near-Infrared Contrast Agents for Bone-Targeted Imaging.Tissue engineering and regenerative medicine · 2019
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. OpticalOncotarget · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Floris P R VerbeekDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Joost R van der Vorst
Quirijn R J G Tummers
Martin C Boonstra
Karien E de Rooij
Clemens W G M Löwik
A Rob P M Valentijn
Cornelis J H van de Velde
Hak Soo Choi
John V Frangioni
Alexander L Vahrmeijer

Funding

Intraoperative Near-Infrared Fluorescence ImagingR01CA115296 · NCI · CURADEL, LLC · PI FRANGIONI, JOHN V · 2005 to 2014
$13.9M
Ultra-Low Background NIR Fluorophores for In Vivo Imaging and Image-Guided SurgerR01EB010022 · NIBIB · CURADEL, LLC · PI FRANGIONI, JOHN V · 2010 to 2013
$2.8M
Image-Guided Surgery of Endocrine Glands and Their Tumors using Near-Infrared FluR01EB011523 · NIBIB · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHOI, HAK SOO · 2010 to 2013
$2.0M
NCI NIH HHS R01 CA115296NCI NIH HHS R01-CA-115296NIBIB NIH HHS R01 EB010022NIBIB NIH HHS R01-EB-010022NIBIB NIH HHS R01 EB011523NIBIB NIH HHS R01-EB-011523
6 · The paper itself

Abstract

backgroundIrradical tumor resections and iatrogenic ureteral injury remain a significant problem during lower abdominal surgery. The aim of the current study was to intraoperatively identify both colorectal tumors and ureters in subcutaneous and orthotopic animal models using cRGD-ZW800-1 and near-infrared (NIR) fluorescence.

methodsThe zwitterionic fluorophore ZW800-1 was conjugated to the tumor specific peptide cRGD (targeting integrins) and to the a-specific peptide cRAD. One nmol cRGD-ZW800-1, cRAD-ZW800-1, or ZW800-1 alone was injected in mice bearing subcutaneous HT-29 human colorectal tumors. Subsequently, cRGD-ZW800-1 was injected at dosages of 0.25 and 1 nmol in mice bearing orthotopic HT-29 tumors transfected with luciferase2. In vivo biodistribution and ureteral visualization were investigated in rats. Fluorescence was measured intraoperatively at several time points after probe administration using the FLARE imaging system.

resultsBoth subcutaneous and orthotopic tumors could be clearly identified using cRGD-ZW800-1. A significantly higher signal-to-background ratio was observed in mice injected with cRGD-ZW800-1 (2.42 ± 0.77) compared with mice injected with cRAD-ZW800-1 or ZW800-1 alone (1.21 ± 0.19 and 1.34 ± 0.19, respectively) when measured at 24 h after probe administration. The clearance of cRGD-ZW800-1 permitted visualization of the ureters and also generated minimal background fluorescence in the gastrointestinal tract.

conclusionsThis study appears to be the first to demonstrate both clear tumor demarcation and ureteral visualization after a single intravenous injection of a targeted NIR fluorophore. As a low dose of cRGD-ZW800-1 provided clear tumor identification, clinical translation of these results should be possible.

Indexed as

Fluorescent DyesPeptides, CyclicQuaternary Ammonium CompoundsSulfonic AcidsUreterAnimalsColorectal NeoplasmsFemaleHT29 CellsHumansIntegrinsIntraoperative PeriodMiceNeoplasm TransplantationOptical Imagingcyclic arginine-glycine-aspartic acid peptideFluorescent DyesIntegrinsPeptides, CyclicQuaternary Ammonium CompoundsSulfonic AcidsZW800-1 compound

Identifiers

PMID24515567
PMCPMC4128907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.